Proposal for changes to funded haemophilia treatments

29 January 2019 - PHARMAC is proposing to make changes to the funding of haemophilia treatments from 1 May 2019, ...

Read more →

PHARMAC publishes PTAC outcome for nivolumab in renal cell carcinoma

22 January 2019 - The Committee reviewed the application for nivolumab for the second-line treatment of relapsed clear cell renal ...

Read more →

PTAC recommends Keytruda for patients with non-small cell lung cancer

22 January 2019 - PTAC reviewed an application from Merck Sharpe and Dohme for the funding of pembrolizumab in combination ...

Read more →

Notification of decision involving treatments for multiple sclerosis, narcolepsy, and attention deficit hyperactivity disorder

11 January 2019 - PHARMAC is pleased to announce the approval of a multi-product agreement with Teva Pharma New Zealand ...

Read more →

Decision to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole

10 January 2019 - PHARMAC is pleased to announce its decision to approve a multi-product agreement with Merck Sharpe & ...

Read more →

PHARMAC funding decision gives Kiwis with hepatitis C access to a potential cure

17 December 2018 - Life changing treatment for New Zealanders living with hepatitis C will be available from 1 February ...

Read more →

Decision to fund a new hepatitis C treatment (Maviret) and to widen access to adalimumab (Humira) for psoriasis

17 December 2018 - PHARMAC is pleased to announce a decision to fund a new treatment for chronic hepatitis C ...

Read more →

Decision in relation to infliximab, tocilizumab and rituximab

14 December 2018 - PHARMAC is pleased to announce a decision on how three hospital medicines (infliximab, tocilizumab and rituximab) ...

Read more →

NZ patients with ALK positive non-small-cell lung cancer score a minor win

23 October 2018 - PTAC has recommended that alectinib hydrochloride be funded for the first-line treatment of ALK positive, locally ...

Read more →

Decision to fund sapropterin

28 September 2018 - PHARMAC is pleased to announce a decision to list sapropterin (Kuvan), a treatment for the rare ...

Read more →

Decision to list nintedanib (Ofev) and remove restrictions from tiotropium bromide (Spiriva)

12 September 2018 - PHARMAC is pleased to announce a decision to list nintedanib (Ofev) and remove the current Special ...

Read more →

Approval of multi-product funding agreement with Novartis

6 September 2018 - PHARMAC is pleased to announce a major funding package involving ten medicines in seven key therapy ...

Read more →

New agreement makes more medicines available to treat range of health conditions

6 September 2018 - Up to 50,000 New Zealanders per year will benefit from a new multiproduct agreement PHARMAC has ...

Read more →

PTAC defers submission for new indication for PD-L1 antagonist

27 July 2018 -  This time its for patients with Hodgkin's disease. The reason; PTAC wants to see updated data ...

Read more →

PTAC recommends immune checkpoint inhibitors for certain patients with advanced urothelial carcinoma

25 July 2018 -  The publication of the minutes of the May 2018 PTAC meeting reveals new outcomes. ...

Read more →